the analysts / brokers are being conservative - it's easy for them - once gsk get to 190m /yr they just rerate it.
not too good if you are trying to get an accurate forcast for investment though.
from what we have experienced with forcasts and biota over the past three mths - i am now convinced that most of them are a bunch of idiots.
